Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL837517 | 0.83 | ALDH1A1 (0.37) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL23036832 | 0.73 | PLA2G2A (0.39) | MAPTALDH1A1RECQLKDM4EMEN1 | |
| SCHEMBL828694 | 0.72 | MAPT (0.49) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL15218061 | 0.72 | MAPT (0.66) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL6843793 | 0.71 | MAPT (0.48) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL28738543 | 0.71 | SLC7A5 (0.50) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL23120097 | 0.71 | SLC7A5 (0.50) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL23120674 | 0.71 | MAPT (0.51) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL1520299 | 0.71 | MAPT (0.48) | MAPTALDH1A1RECQLSLC7A5ALPI | |
| SCHEMBL1520373 | 0.71 | ALDH1A1 (0.48) | MAPTALDH1A1RECQLSLC7A5ALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109142-A1 | CORONA VIRUS VACCINE | IMMUNOR AS (NO) | 2023-04-06 | — | — | US | disclosed |
| EP-2646459-B1 | PEPTIDE SCAFFOLD DESIGN | BIONOR IMMUNO AS (NO) | 2020-01-08 | — | — | EP | disclosed |
| US-10501499-B2 | Peptides derived from viral proteins for use as immunogens and dosage reactants | BIONOR IMMUNO AS (NO) | 2019-12-10 | — | — | US | disclosed |
| US-10124059-B2 | Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes | BIONOR IMMUNO AS (NO) | 2018-11-13 | — | — | US | disclosed |
| EP-3338798-A1 | MULTIMERIC PEPTIDE | Bionor Immuno AS (NO) | 2018-06-27 | — | — | EP | disclosed |
| US-20170112917-A1 | PEPTIDE SCAFFOLD DESIGN | BIONOR IMMUNO AS (NO) | 2017-04-27 | — | — | US | disclosed |
| US-9550811-B2 | Peptide scaffold design | BIONOR IMMUNO AS (NO) | 2017-01-24 | — | — | US | disclosed |
| US-20160375129-A1 | DIMERIC SCAFFOLD PEPTIDES COMPRISING HIV-1 GP120 AND GP41 EPITOPES | BIONOR IMMUNO AS (NO) | 2016-12-29 | — | — | US | disclosed |
| US-9493514-B2 | Dimeric scaffold proteins comprising HIV-1 GP120 and GP41 epitopes | BIONOR IMMUNO AS (NO) | 2016-11-15 | — | — | US | disclosed |
| CN-103347892-B | Monomer and polymer immunogenic peptide | 比奥诺尔免疫有限公司 | 2016-11-02 | — | — | CN | disclosed |
| US-20130337002-A1 | PEPTIDE SCAFFOLD DESIGN | BIONOR IMMUNO AS (NO) | 2013-12-19 | — | — | US | disclosed |
| EP-2661442-A1 | MONOMERIC AND MULTIMERIC IMMUNOGENIC PEPTIDES | Bionor Immuno AS (NO) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012092934-A1 | MONOMERIC AND MULTIMERIC IMMUNOGENIC PEPTIDES | BIONOR IMMUNO AS (NO) | 2012-07-12 | — | — | WO | disclosed |
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2012-05-03 | — | — | US | disclosed |
| US-8048852-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2011-11-01 | — | — | US | disclosed |
| EP-1263471-B1 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | LYTIX BIOPHARMA AS (NO) | 2011-10-12 | — | — | EP | disclosed |
| EP-2338522-A1 | Antitumoural therapies | Lytix Biopharma AS (NO) | 2011-06-29 | — | — | EP | disclosed |
| US-20100267621-A1 | Antimicrobial Compounds and Formulations | LYTIX BIOPHARMA AS (NO) | 2010-10-21 | — | — | US | disclosed |
| US-7232803-B2 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2007-06-19 | — | — | US | disclosed |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LYTIX BIOPHARMA AS (NO) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108520-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | MAPT 3958/4885ALDH1A1 4792/4885RECQL 3826/4885 |
| US-20100267621-A1 | Antimicrobial Compounds and Formulations | VIP, NONO, CLPTM1 | MAPT 3958/4885ALDH1A1 4792/4885RECQL 3826/4885 |
| US-20160375129-A1 | DIMERIC SCAFFOLD PEPTIDES COMPRISING HIV-1 GP120 AND GP41 EPITOPES | CD4, HAVCR2, MAVS | MAPT 1611/4885ALDH1A1 4860/4885RECQL 3492/4885 |
| US-10124059-B2 | Dimeric scaffold peptides comprising HIV-1 GP120 and GP41 epitopes | CD4, HAVCR2, MAVS | MAPT 1611/4885ALDH1A1 4860/4885RECQL 3492/4885 |
| US-20230109142-A1 | CORONA VIRUS VACCINE | CALCA, HCFC1, STING1 | MAPT 3352/4885ALDH1A1 2638/4885RECQL 3820/4885 |
| US-20030195144-A1 | Antimicrobial compounds and formulations | LPO, CLPTM1, VIP | MAPT 4459/4885ALDH1A1 4708/4885RECQL 3950/4885 |
| US-10501499-B2 | Peptides derived from viral proteins for use as immunogens and dosage reactants | HAVCR2, CXCL10, CCL5 | MAPT 2043/4885ALDH1A1 3747/4885RECQL 2030/4885 |
| US-20130337002-A1 | PEPTIDE SCAFFOLD DESIGN | CXCR4, CCL5, CXCR5 | MAPT 1757/4885ALDH1A1 4782/4885RECQL 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.